Viking Therapeutics, Inc. (0VQA.L)
USD 39.07
(-17.95%)
USD 39.07
(-17.95%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 368.49 Million USD | 118.65% |
| 2022 | 168.52 Million USD | -20.0% |
| 2021 | 210.66 Million USD | -17.87% |
| 2020 | 256.5 Million USD | -9.76% |
| 2019 | 284.25 Million USD | -5.97% |
| 2018 | 302.31 Million USD | 1266.6% |
| 2017 | 22.12 Million USD | 52.19% |
| 2016 | 14.53 Million USD | -5.85% |
| 2015 | 15.43 Million USD | 407.34% |
| 2014 | 3.04 Million USD | 1586.94% |
| 2013 | 180.39 Thousand USD | 0.0% |
| 2012 | - USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 937.88 Million USD | -0.95% |
| 2024 Q2 | 946.83 Million USD | -2.14% |
| 2024 Q1 | 967.51 Million USD | 162.56% |
| 2023 Q1 | 150.89 Million USD | -10.46% |
| 2023 Q3 | 382.66 Million USD | -4.5% |
| 2023 Q2 | 400.69 Million USD | 165.54% |
| 2023 Q4 | 368.49 Million USD | -3.7% |
| 2023 FY | 368.49 Million USD | 118.65% |
| 2022 Q2 | 181.5 Million USD | -6.93% |
| 2022 Q4 | 168.52 Million USD | 1.11% |
| 2022 Q3 | 166.68 Million USD | -8.17% |
| 2022 FY | 168.52 Million USD | -20.0% |
| 2022 Q1 | 195.02 Million USD | -7.42% |
| 2021 Q2 | 237.84 Million USD | -4.91% |
| 2021 FY | 210.66 Million USD | -17.87% |
| 2021 Q1 | 250.13 Million USD | -2.48% |
| 2021 Q4 | 210.66 Million USD | -6.15% |
| 2021 Q3 | 224.47 Million USD | -5.62% |
| 2020 FY | 256.5 Million USD | -9.76% |
| 2020 Q4 | 256.5 Million USD | -2.7% |
| 2020 Q1 | 277.1 Million USD | -2.52% |
| 2020 Q2 | 271.19 Million USD | -2.13% |
| 2020 Q3 | 263.62 Million USD | -2.79% |
| 2019 Q2 | 294.49 Million USD | -1.86% |
| 2019 Q4 | 284.25 Million USD | -2.02% |
| 2019 Q3 | 290.12 Million USD | -1.48% |
| 2019 Q1 | 300.08 Million USD | -0.74% |
| 2019 FY | 284.25 Million USD | -5.97% |
| 2018 Q1 | 78.97 Million USD | 256.99% |
| 2018 FY | 302.31 Million USD | 1266.6% |
| 2018 Q4 | 302.31 Million USD | -1.46% |
| 2018 Q3 | 306.79 Million USD | 112.36% |
| 2018 Q2 | 144.46 Million USD | 82.94% |
| 2017 Q4 | 22.12 Million USD | 86.85% |
| 2017 Q3 | 11.83 Million USD | -17.33% |
| 2017 Q2 | 14.32 Million USD | -5.49% |
| 2017 Q1 | 15.15 Million USD | 4.24% |
| 2017 FY | 22.12 Million USD | 52.19% |
| 2016 Q1 | 12.75 Million USD | -17.37% |
| 2016 Q4 | 14.53 Million USD | -10.92% |
| 2016 Q3 | 16.31 Million USD | -12.03% |
| 2016 Q2 | 18.54 Million USD | 45.4% |
| 2016 FY | 14.53 Million USD | -5.85% |
| 2015 Q1 | 2.76 Million USD | -9.0% |
| 2015 Q2 | 22.26 Million USD | 704.16% |
| 2015 Q3 | 19.01 Million USD | -14.63% |
| 2015 Q4 | 15.43 Million USD | -18.79% |
| 2015 FY | 15.43 Million USD | 407.34% |
| 2014 Q1 | 276.71 Thousand USD | 53.4% |
| 2014 Q2 | 2.01 Million USD | 627.85% |
| 2014 FY | 3.04 Million USD | 1586.94% |
| 2014 Q4 | 3.04 Million USD | 0.0% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | 180.39 Thousand USD | 0.0% |
| 2013 Q3 | 180.39 Thousand USD | 0.0% |
| 2013 FY | 180.39 Thousand USD | 0.0% |
| 2012 FY | - USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Editas Medicine, Inc. | 499.15 Million USD | 26.177% |
| Dynavax Technologies Corporation | 997.09 Million USD | 63.044% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 73.847% |
| Perrigo Company plc | 10.8 Billion USD | 96.591% |
| Illumina, Inc. | 10.11 Billion USD | 96.356% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 99.627% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | 52.779% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 99.545% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 98.619% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -65.609% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 98.886% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -460.953% |
| Waters Corporation | 4.62 Billion USD | 92.036% |
| Biogen Inc. | 26.84 Billion USD | 98.627% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -122.895% |
| Evolus, Inc. | 188.99 Million USD | -94.97% |
| Adicet Bio, Inc. | 207.29 Million USD | -77.761% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -192.815% |
| bluebird bio, Inc. | 619.16 Million USD | 40.486% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -79.056% |
| FibroGen, Inc. | 423.52 Million USD | 12.995% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 96.576% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -1203.356% |
| Homology Medicines, Inc. | 47.05 Million USD | -683.072% |
| Geron Corporation | 394.07 Million USD | 6.493% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 90.379% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | 52.629% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 69.259% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 71.676% |
| Zoetis Inc. | 14.28 Billion USD | 97.421% |
| Abeona Therapeutics Inc. | 64 Million USD | -475.748% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 89.019% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 94.614% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 98.379% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -558.618% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 87.676% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -122.647% |
| Verastem, Inc. | 149.71 Million USD | -146.123% |
| Nektar Therapeutics | 398.03 Million USD | 7.422% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | 37.357% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -86.667% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 88.712% |
| OPKO Health, Inc. | 2.01 Billion USD | 81.683% |
| Exelixis, Inc. | 2.94 Billion USD | 87.476% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 88.667% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | 40.711% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -138.681% |
| uniQure N.V. | 831.68 Million USD | 55.694% |
| Imunon, Inc. | 21.91 Million USD | -1581.216% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 64.881% |
| Insmed Incorporated | 1.32 Billion USD | 72.291% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 78.74% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 60.678% |
| TG Therapeutics, Inc. | 329.58 Million USD | -11.804% |
| Incyte Corporation | 6.78 Billion USD | 94.567% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 79.918% |